Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. (NTRA) Form 144 notice shows proposed and recent sales of common stock by Solomon Moshkevich. The filer plans to sell 3,000 shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $499,864.50 based on the filing. The issuer has 137,248,106 shares outstanding per the form. The seller acquired the 3,000 shares being offered as restricted stock and performance shares between 12/20/2024 and 01/26/2025 (lots of 818, 1,648, 292 and 242 shares). In the past three months the same person sold a total of 9,372 shares across five transactions (dates from 07/01/2025 to 08/14/2025) generating gross proceeds of approximately $1,482,439 as listed on the form. The filing includes standard Rule 144 attestations but does not provide a filer CIK or contact details in the visible tables.
Natera, Inc. (NTRA) filing of Form 144 notifies the SEC of a proposed sale of 2,750 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $459,222.50. The shares represent part of a restricted stock grant acquired from the issuer on 06/09/2024.
The filing lists an approximate sale date of 08/28/2025 and reports 137,248,106 shares outstanding. The filer states there were no securities sold in the past three months and makes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Moshkevich Solomon, President, Clinical Diagnostics at Natera, Inc. (NTRA), reported equity transactions relating to previously granted restricted stock units. On 08/12/2025, 1,675 RSUs vested after certification of milestone achievement; each RSU converts into one share. Following vesting the reporting person beneficially owned 124,734 shares. On 08/14/2025 the reporting person sold 867 shares at $155.46 and 8 shares at $155.4248 to satisfy tax withholding obligations under a written instruction intended to meet Rule 10b5-1 affirmative defense, leaving 123,859 shares beneficially owned. The Form 4 is signed by an attorney-in-fact on 08/15/2025.
Insider stock vesting and related sales at Natera, Inc. (NTRA). The reporting person had 1,675 restricted stock units (RSUs) vest upon certification that specific time- and performance-based milestones were met; each RSU converts into one share of common stock. Following vesting, the reporting person beneficially owned 153,425 shares before share disposals. To satisfy tax withholding obligations tied to the vesting, the filer sold 678 shares in two transactions at prices of $155.46 and $155.30, leaving 152,747 shares beneficially owned after the reported activity. The sales were made pursuant to a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1.
In this Form 4, Natera director and co-founder Sheena Jonathan reported sales totaling 6,070 shares of Natera common stock: 3,070 shares on 08/08/2025 and 3,000 shares on 08/11/2025. The filing lists weighted-average prices for the 08/08 sales roughly in the mid-$156 to mid-$164 range and for the 08/11 sales roughly in the low-$150 to mid-$156 range. Footnotes state the 08/08 sales were executed under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were executed under a separate Rule 10b5-1 plan adopted June 7, 2024.
Following these transactions the reporting person retained 242,252 shares reported as directly owned and reported indirect trust holdings associated with Caraluna trusts in the ~34,282–35,662 share range across the trust entries. No derivative securities were reported.
Insider Form 4 filing — Natera, Inc. (NTRA)
On 08/01/2025, Solomon Moshkevich (President, Clinical Diagnostics; officer) reported three sales of Natera common stock effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024. The reported dispositions were 1,574 shares at a weighted-average price of $132.4528 (range $131.9350–$132.78), 1,326 shares at $133.3097 (range $132.96–$133.80), and 100 shares at $134.08.
Post-transaction beneficial ownership: reported as 124,485; 123,159; and 123,059 shares respectively. The Form was signed by an attorney-in-fact on 08/05/2025.